Synverus uses cloud-scale computational chemistry and comparative biology to discover novel therapeutics — with companion animals as the translational bridge to human medicine. They benefit first. We all benefit faster.
Get in touchThe most exciting therapeutic targets emerging from human pharmaceutical research address biology that is deeply conserved across species. The same inflammatory pathways, the same degenerative mechanisms, the same unmet needs — in both humans and the animals who share our homes.
Synverus starts with these shared targets and applies compute-intensive AI and molecular simulation to find novel chemical matter. By validating in companion animal populations first — where disease biology mirrors human disease, regulatory timelines are shorter, and clinical need is acute — we generate real-world translational evidence that accelerates the path to human therapeutics.
Our companion animals get early access to cutting-edge medicines. In return, they provide something no preclinical model can: authentic translational data from naturally occurring disease in a shared environment.
Naturally occurring disease, conserved biology, shorter development cycles. Early access to novel mechanisms.
Real-world translational evidence from natural disease. De-risked targets, validated mechanisms, accelerated timelines.
We select targets where human and companion animal biology overlap — same pathways, same disease mechanisms, validated by genomic and structural evidence.
Companion animals develop diseases naturally — not through artificial induction. This generates translational evidence of a quality no rodent model can match.
Every programme we advance has a clear path in both veterinary and human markets, creating multiple routes to value and strategic flexibility at every stage.
Our proprietary engine navigates billion-compound chemical spaces using machine learning and structural data, running large-scale docking campaigns on cloud GPU and CPU clusters to identify novel scaffolds with optimised target engagement.
Physics-based molecular docking, GPU-accelerated neural network scoring, and ensemble machine learning models work in concert — evaluating compounds across binding, selectivity, and developability at scale.
Structure–activity models trained on docking decomposition data don't just predict — they explain. Region-specific guidance tells our chemists where to optimise and why, tightening the compute–design feedback loop.
Automated protein structure alignment and comparative docking across species ensures every candidate is designed for conserved binding sites — so what works in one population translates to others.
Our pipeline targets validated mechanisms at the intersection of human and companion animal disease — areas where conserved biology, clinical unmet need, and computational tractability converge. All programmes are in computational lead discovery.
We're open to conversations with potential partners, collaborators, and investors interested in the convergence of AI, translational biology, and comparative medicine.
Early-stage, AI-first R&D company. Cloud compute is core to our discovery engine. Actively seeking grant funding and strategic partnerships.